Edwards Lifesciences Corporation $EW Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 10.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 100,515 shares of the medical research company’s stock after selling 12,150 shares during the period. Jacobs & Co. CA’s holdings in Edwards Lifesciences were worth $8,568,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $25,000. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after acquiring an additional 164 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in Edwards Lifesciences in the third quarter valued at $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total value of $974,446.20. Following the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,897,284.92. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 61,718 shares of company stock valued at $5,236,281. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 1.9%

Shares of Edwards Lifesciences stock opened at $82.68 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The company has a market capitalization of $48.02 billion, a P/E ratio of 45.18, a PEG ratio of 2.20 and a beta of 0.93. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The company’s fifty day moving average is $82.32 and its two-hundred day moving average is $81.63.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the company posted $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Citigroup reiterated a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Piper Sandler restated an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.